Pfizer and Amgen target GLP-1 weight-loss market to rival Novo Nordisk and Eli Lilly
read at STAT ↗Neutral
The STATus Report video hosted by Alex Hogan discusses the growing GLP-1 weight-loss drug market.
Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound have been on the market for a few years and are popular.
Pfizer, Amgen and other companies are developing similar GLP-1 agents to capture market share.
The segment also includes commentary from "The Readout LOUD" podcast on the rapid evolution of GLP-1 therapies.
source
This writeup was produced by pharmadog from original reporting by STAT.
Original headline: “What’s next for GLP-1 weight loss drugs?”
read at STAT ↗336 words · retrieved Jun 18
comments(0)
5-min edit window · permanent after that